Novo Nordisk and Eli Lilly to Share GLP-1 Market Growth, Says Citi Analyst

Obesity Drug Market Competition

• 💡 The competition between Novo Nordisk and Eli Lilly in the obesity drug market is expected to be dramatic this year, but it's not a zero-sum game.
• 🎯 Both companies are projected to gain market share due to broader access, including benefits from the Medicare Medicaid agreement.
• 🚀 The Wegovy pill and an Amazon deal are highlighted as significant wins for Novo Nordisk, potentially reaching 220 million US Prime members.

Emerging Players and Development Hurdles

• 🔬 Smaller companies like Structure, Viking, Metsera, and Pfizer are working on next-generation weight loss drugs, but face high bars set by Lilly and Novo.
• 🔑 Success requires not only high efficacy but also great tolerability and low dropout rates, with phase three trials being the true test.
• 💰 Smaller players may need deeper pockets or corporate partners to fund large-scale phase three trials.

Key Industry Themes and Events

• 🗓️ The upcoming JP Morgan Healthcare conference is expected to feature obesity as a major theme, with potential for deal announcements.
• 📈 Other themes include management teams validating a quieter policy environment compared to last year, and expected IPO activity.
• 🤖 The role of AI in speeding up drug development timelines is also a significant topic of discussion.

Market Dynamics and Valuations

• 📊 While Novo and Lilly are expected to dominate the market by 2030-2032, there is room for two or three additional players.
• ⚠️ Companies like Pfizer, Roche, and smaller players like Metsera and Structure are not to be counted out, but their path to success is challenging.
• 🤝 The current market environment suggests that significant efficacy and tolerability are key differentiators for new entrants.